MRT-2359 & ApalutamideStudy of Oral MRT-2359 With Apalutamide in Prostate Cancer

Sponsor:

Monte Rosa Therapeutics, Inc

Code:

NCT07745361

Conditions

Castration-Resistant Prostate Cancer (CRPC)

Castration-Resistant Prostate Cancer

Prostate Cancer

Prostate Cancer (Adenocarcinoma)

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Oral MRT-2359

Apalutamide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-24. This information was provided to ClinicalTrials.gov by Monte Rosa Therapeutics, Inc on 2026-08-04.